Barbara Jo Nelson, PHARMD in London, KY - Pharmacist

Barbara Jo Nelson, PHARMD is a Pharmacist based in London, Kentucky. Barbara Jo Nelson is licensed to practice in Kentucky (license number 011830) and her current practice location is 1775 Highway 192 W, London, Kentucky. She can be reached at her office (for appointments etc.) via phone at (606) 877-2727.

NPI number for Barbara Jo Nelson is 1144504838 and her current mailing address is Po Box 3191, London, Kentucky. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1144504838.

Contact Information

	Barbara Jo Nelson, PHARMD
	1775 Highway 192 W, London, KY 40741-1676
	(606) 877-2727
	Not Available

Healthcare Provider's Profile

Full Name	Barbara Jo Nelson
Gender	Female
Speciality	Pharmacist
Location	1775 Highway 192 W, London, Kentucky
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1144504838
Provider Enumeration Date: 09/29/2011
Last Update Date: 09/29/2011

Medical Identifiers

Medical identifiers for Barbara Jo Nelson such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1144504838	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
183500000X	Pharmacist	011830 (Kentucky)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Barbara Jo Nelson is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Barbara Jo Nelson, PHARMD Po Box 3191, London, KY 40743-3191 Ph: (859) 979-3949	Barbara Jo Nelson, PHARMD 1775 Highway 192 W, London, KY 40741-1676 Ph: (606) 877-2727

News Archive

Sigma-Aldrich, NHLBI and BU collaborate in atherosclerotic cardiovascular disease research

Sigma-Aldrich® today announced it has entered into an agreement with the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health, and Boston University (BU) to develop methods to measure several potential biomarkers of atherosclerotic cardiovascular disease (CVD) using plasma samples from the NHLBI's Framingham Heart Study (FHS), one of the most prestigious clinical studies in medicine. Funding for the project is provided by the NHLBI to Sigma-Aldrich under a research subaward agreement with BU.

Partisan sniping dominates Senate health debate

The Christian Science Monitor: In the coming days, "senators will have to grind through lots of [amendments], as members of both parties line up to try and shape the final product. ... Senate debate on Tuesday began at around 2:15 pm, and quickly formed along expected lines. Sen. Charles Grassley (R) of Iowa, ranking minority member on the Finance Committee, led off by complaining about the size and possible expense of the effort, layered on top of federal bailouts of banks and auto firms.

FDA grants Cerexa fast track designation

Cerexa has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for PPI-0903, a next-generation, broad-spectrum, cephalosporin antibiotic, for the treatment of complicated skin and skin structure infections (cSSSI) caused by methicillin-resistant Staphylococcus aureus (MRSA).

Obama administration moves forward on employer mandate

A signal came Thursday when the Internal Revenue Service posted drafts of forms that employers will have to fill out to comply with the requirement that they provide workers with health insurance.

Anavex comments on new Alzheimer's disease diagnostic guidelines

Anavex Life Sciences Corp. ("Anavex") (OTCBB: AVXL) today commented on new diagnostic criteria and guidelines for Alzheimer's disease published recently by the National Institute on Aging (NIA) and the Alzheimer's Association, which have been updated for the first time in more than 25 years. The new guidelines discuss the importance of new technologies, including brain imaging and biomarker analysis, in research and clinical diagnosis. They describe Alzheimer's disease at a preclinical stage, Mild Cognitive Impairment (MCI) due to Alzheimer's disease, and dementia due to Alzheimer's pathology.

Pharmacist in London, KY

Francis Britton Thompson, R.PH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 810 E 4th St, London, KY 40741 Phone: 606-878-7713
Timothy Scott Lawson, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1775 Highway 192 W, London, KY 40741 Phone: 606-877-2727
Angelia Denise Hicks, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1851 Highway 192 W, London, KY 40741 Phone: 606-878-3041 Fax: 600-877-3041
Dr. Brooke Feltner, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 810 E 4th St, London, KY 40741 Phone: 606-878-7713 Fax: 606-878-9458
Mary N Casebolt, R.PH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 237 Parkway Hls, London, KY 40741 Phone: 606-878-1486
Britney Morgan, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1730 Highway 192 W, London, KY 40741 Phone: 606-878-1568
Mr. Donald R Baker, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 803 Meyers Baker Rd Ste 110, London, KY 40741 Phone: 606-877-1008 Fax: 606-864-3127

Barbara Jo Nelson, PHARMD - Pharmacist in London, KY